Trastuzumab-deruxtecan has already been validated in the management of HER2-overexpressing breast cancer [71], and it is currently undergoing phase III evaluation in HER2-overexpressing gastric cancer with very encouraging results [72,73]. This evidence concerns the gene ERBB2 and breast carcinoma.